Pierre Fabre Medicament

Marie Lamothe

Michel Perez

Ian Rilatt

Liliane Goetsch

Jean-François Haeuw

Charlotte Beau-Larvor

Matthieu Broussas

Bruno Le Grand

Alain Robert

Thierry Champion

Robert Letienne

Alexandra Jouhanneaud

Didier Junquero

Yves Rival

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.

Antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

IGF-1R antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drag selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drag-conjugate for the treatment of cancer.

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatinand auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

Composition for the treatment of IGF-1R expressing cancer

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11&#x3b2;-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably Rrepresents a hydrogen or OR1 represents an ester or an ether. Rrepresents a naphthyl or a 1,2,3,4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. Rrepresents a methyl or ethyl; Rand R'represent a hydrogen. 

Derivatives of benzothiazines, preparation thereof and application thereof as drugs

The present invention relates to compounds of general formula (I):  These compounds are useful as protease-activated receptor-1 (PAR-1) antagonists, particularly in the treatment of thrombosis.

Cinnamoyl-piperazine derivatives and their use as par-1 antagonists

The present invention relates to compounds of general formula (I): wherein: These compounds are useful as protease-activated receptor-1 (PAR-1) antagonists, particularly in the treatment of thrombosis.

Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists

The present invention relates to compounds of general formula (I): wherein: Rand R, identical or different, represent: an atom of hydrogen or halogen, CN or NO, with Rand Rnot representing hydrogen simultaneously, m represents: 1 or 2 n represents: 0, 1 or 2 Rrepresents: phenyl substituted or not by one or more residues chosen among halogen, hydroxyl or C-Calkyl; C-Calkyl substituted or not by one or more residues chosen among halogen or hydroxyl; cycloalkyl; pyridine; thiophene; pyrrole substituted or not by C-Calkyl; thiazole or furan; or the therapeutically-acceptable salts or solvates thereof. 

Growing community of inventors

Montredon Labessonnie, France

Marie Lamothe